HIF1A and familial pancreatic carcinoma: The expression of miR-142 is also significantly reduced in patients with pancreatic cancer, and this inhibits the expression of HIF1A and PARK7, which enhances the sensitivity of the pancreatic cancer cells to adriamycin [125,126].